Biofrontera will yank shares from Nasdaq; Intellia and ONK collaborate on cancer candidates
German biopharma Biofrontera has decided to delist its shares from the Nasdaq and deregister its reporting obligations with the SEC in an attempt to reduce complexity in financial reporting and administrative costs.
The company’s ordinary shares will still be traded in the Prime Standard at the Deutsche Börse under the symbol B8F. American shareholders can choose to exchange their American Depositary Shares for ordinary shares on the Deutsche Börse, the company said in a release.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
